Uropathogen resistance: Are laboratory-generated data reliable enough?

Journal of Chemotherapy

Volumn 19, Issue 1, 2007, Pages 33-37

  Lopardo, G ^a,b,e   Fridman, D ^b   Gonzalez Arzac, M ^a   Calmaggi, A ^a   Smayevsky, J ^c   Podesta, O ^b   Clara, L ^a,d  

^a Sociedad Argentina de Infectología Pediátrica   (Argentina)

^b Centro Stamboulian   (Argentina)

^c CEMIC   (Argentina)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e NONE   (Argentina)

Author keywords

Bacterial resistance; Uncomplicated; bacteria; Urinary tract infection

Indexed keywords

AMPICILLIN; CEFALOTIN; CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN; SULTAMICILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG SENSITIVITY; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION SENSITIVITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATHOGENESIS; RANDOM SAMPLE; RELIABILITY; URINALYSIS; URINARY TRACT INFECTION;

EID: 33846958729     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.1.33     Document Type: Article

References (13)

1. Ti TY, Kumarasinghe G, Taylor MB, et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis 2003;22: 242-5.
2. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29: 745-58.
3. Winstanley TG, Limb DI, Eggington R, Hancock F. A 10 year survey of the antimicrobial susceptibility of urinary tract isolated in the UK: the Microbe Base Project. J Antimicrob Chemother 1997; 40:591-4.
4. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999;281:736-738.
5. Ronald AR, Harding GKM. Complicated urinary tract infections. Infect Dis Clin North Am 1997; 11:583-92.
6. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; Suppl 1:S216-27.
7. National Committee for Laboratory Standards (NCCLS). Document M100-S12. Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement MIC testing, 2002.
8. Goldstein FW, the Multicentre Study Group. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 2000; 119:112-7.
9. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS project. J Antimicrob Chemother 2003;51:69-76.
10. Klugman KP. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin Infect Dis 2003; 36: 783-5.
11. Naber KG, Bergman B, Bishop MC et al. EAU guidelines for the management of urinary tract infection. Eur Urol 2001; 40: 576-88.
12. Marchetti F. Can the susceptibility results of 512 clinical isolated Escherichia coli obtained from a selected female population be generalized to the whole community? J Chemother 2005; 17: 566-7.
13. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11: 551-81.